FDA pharmacologic class
Neonatal Fc Receptor Blocker
2 medicines are in FDA's class of neonatal Fc receptor blockers: rozanolixizumab (Rystiggo) and efgartigimod alfa (Vyvgart); 1 combination product also contains one. 0 of the 3 are listed from generic labelers (FDA NDC Directory, October 8, 2026).
Which medicines are neonatal fc receptor blocker?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Rozanolixizumab | Rystiggo | none listed | n/a | No | No current entry | 0 |
| Efgartigimod alfa and hyaluronidase | Vyvgart | none listed | n/a | No | No current entry | 0 |
| Efgartigimod alfa | Vyvgart | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)